Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Bibliographic Details
Main Authors: Benjamin A. Derman, Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, Andrzej J. Jakubowiak
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00418-2
id doaj-91b32f38a75d447da8354e045fdda7dc
record_format Article
spelling doaj-91b32f38a75d447da8354e045fdda7dc2021-02-14T12:10:57ZengNature Publishing GroupBlood Cancer Journal2044-53852021-02-011121410.1038/s41408-021-00418-2Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantationBenjamin A. Derman0Andrew T. Stefka1Ken Jiang2Amanda McIver3Tadeusz Kubicki4Jagoda K. Jasielec5Andrzej J. Jakubowiak6Section of Hematology/Oncology, University of Chicago Medical CenterSection of Hematology/Oncology, University of Chicago Medical CenterSection of Hematology/Oncology, University of Chicago Medical CenterSection of Hematology/Oncology, University of Chicago Medical CenterDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical SciencesSection of Hematology/Oncology, University of Chicago Medical CenterSection of Hematology/Oncology, University of Chicago Medical Centerhttps://doi.org/10.1038/s41408-021-00418-2
collection DOAJ
language English
format Article
sources DOAJ
author Benjamin A. Derman
Andrew T. Stefka
Ken Jiang
Amanda McIver
Tadeusz Kubicki
Jagoda K. Jasielec
Andrzej J. Jakubowiak
spellingShingle Benjamin A. Derman
Andrew T. Stefka
Ken Jiang
Amanda McIver
Tadeusz Kubicki
Jagoda K. Jasielec
Andrzej J. Jakubowiak
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
Blood Cancer Journal
author_facet Benjamin A. Derman
Andrew T. Stefka
Ken Jiang
Amanda McIver
Tadeusz Kubicki
Jagoda K. Jasielec
Andrzej J. Jakubowiak
author_sort Benjamin A. Derman
title Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
title_short Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
title_full Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
title_fullStr Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
title_full_unstemmed Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
title_sort measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase ii trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
publisher Nature Publishing Group
series Blood Cancer Journal
issn 2044-5385
publishDate 2021-02-01
url https://doi.org/10.1038/s41408-021-00418-2
work_keys_str_mv AT benjaminaderman measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT andrewtstefka measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT kenjiang measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT amandamciver measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT tadeuszkubicki measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT jagodakjasielec measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
AT andrzejjjakubowiak measurableresidualdiseaseassessedbymassspectrometryinperipheralbloodinmultiplemyelomainaphaseiitrialofcarfilzomiblenalidomidedexamethasoneandautologousstemcelltransplantation
_version_ 1724270896195043328

Similar Items